Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington's disease.
Hands
Sarah L
SL
Neuroscience Group, School of Biological Sciences, University of Southampton, Bassett Crescent East, Southampton SO16 7PX, UK.
Mason
Robert
R
Sajjad
M Umar
MU
Giorgini
Flaviano
F
Wyttenbach
Andreas
A
D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D003300:Copper / Q000378:metabolism* / Q000502:physiology; D016503:Drug Delivery Systems; D005091:Exons / Q000235:genetics; D018390:Gene Targeting; D006367:HeLa Cells; D006706:Homeostasis / Q000235:genetics / Q000502:physiology; D006801:Humans; D000071058:Huntingtin Protein; D006816:Huntington Disease / Q000235:genetics / Q000628:therapy*; D053858:Metabolic Networks and Pathways / Q000235:genetics; D008668:Metallothionein / Q000378:metabolism* / Q000502:physiology; D050505:Mutant Proteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism; D011485:Protein Binding / Q000235:genetics; D012440:Saccharomyces; D014162:Transfection
D002352:Carrier Proteins; C086055:HTT protein, human; D000071058:Huntingtin Protein; D050505:Mutant Proteins; D009419:Nerve Tissue Proteins; D009687:Nuclear Proteins; C023548:copper-binding protein; D003300:Copper; D008668:Metallothionein